Scarica l'app Stockscreener
22.03
5.41%
1.13
Pre-mercato:
22.72
0.69
+3.13%
Neurogene Inc Borsa (NGNE) Ultime notizie
Neurogene (NASDAQ:NGNE) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Neurogene: Q4 Earnings Snapshot - theheraldreview.com
Neurogene Inc. Advances Gene Therapy for Rare Neurological Diseases with EXACT Platform and NGN-401 Clinical Development - Minichart
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway - TipRanks
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neurogene 10-K: Revenue $0.0M, EPS $(4.24) on $90.4M net loss - TradingView
Neurogene (NASDAQ: NGNE) details Rett gene therapy progress and cash runway - Stock Titan
Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome and Advances Toward Commercialization in 2026 - Minichart
William Blair reiterates Neurogene stock rating on trial progress - Investing.com
William Blair reiterates Neurogene stock rating on trial progress By Investing.com - Investing.com Australia
Leerink reiterates Neurogene stock rating on Rett syndrome progress By Investing.com - Investing.com Australia
Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neurogene : Corporate Presentation March 2026 - marketscreener.com
NGN-401 clinical developments and financials drive Neurogene Inc. corporate update - Traders Union
NGNE: NGN-401 advances with full trial enrollment, FDA Breakthrough status, and strong cash runway - TradingView
Neurogene (NGNE) deepens Rett gene therapy push with 2025 loss and long cash runway - Stock Titan
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates - marketscreener.com
BRIEF-Neurogene FY Operating Expenses USD 103.328 Million - TradingView
Rett syndrome gene therapy clears 50% dosing, no HLH cases yet - Stock Titan
Neurogene Inc.: Fundamental Analysis and Financial Ratings | | US64135M1053 - marketscreener.com
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference - MarketBeat
Neurogene Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
Neurogene Inc: chief scientific officer Cobb sells $141k in stock - Investing.com
Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock - MarketBeat
Neurogene (NASDAQ:NGNE) Insider Sells 6,797 Shares - MarketBeat
Neurogene (NGNE) CSO sells 6,797 shares under 10b5-1 plan - Stock Titan
Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed - Stock Titan
Published on: 2026-03-17 03:31:12 - baoquankhu1.vn
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
[144] Neurogene Inc. SEC Filing - Stock Titan
Latest NGNE NewsNeurogene Announces NGN-401 Gene Therapy fo... - Stock Titan
Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Bluefield Daily Telegraph
Genetic-medicine firm Neurogene in Stifel 2026 virtual CNS fireside chat - Stock Titan
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
NGNE: Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans - TradingView
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, with pivotal data expected mid-2024 - TradingView
Gains Recap: Whats the analyst consensus on Neurogene Inc2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Will Neurogene Inc. stock outperform value stocksInsider Buying & Accurate Buy Signal Alerts - Naître et grandir
Aug Update: How correlated is Neurogene Inc to the S P500Chart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Layoff Watch: Is Neurogene Inc part of any major indexJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Aug Movers: Is Neurogene Inc backed by strong institutional buyingJuly 2025 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Macro Review: Is Neurogene Inc in a long term uptrend2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Should You Buy Neurogene Inc (NGNE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neurogene: Stock Soars On FDA Designation For Rett Gene TherapyI'd Remain Cautious - Seeking Alpha
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Neurogene (NASDAQ:NGNE) Now Covered by Canaccord Genuity Group - MarketBeat
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
FDA grants breakthrough therapy status to Neurogene’s Rett drug - Investing.com India
Why Is Neurogene Stock Skyrocketing Friday?Neurogene (NASDAQ:NGNE) - Benzinga
Neurogene : NGNE - 24/7 Wall St.
Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (F - Bitget
Canaccord Genuity initiates coverage of Neurogene (NGNE) with buy recommendation - MSN
Neurogene Gets FDA Breakthrough Tag For NGN-401 In Rett Syndrome; Stock Up - Nasdaq
FDA grants breakthrough therapy status to Neurogene’s Rett drug By Investing.com - Investing.com Australia
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy - TipRanks
Neurogene stock surges 30% on FDA breakthrough therapy status - Investing.com
Neurogene stock surges 30% on FDA breakthrough therapy status By Investing.com - Investing.com Australia
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):